Author

Kaori Igarashi

Institute for Advanced Biosciences, Keio University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:Drosophila· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Tomoyoshi SogaiD· 2 shared David Ernest JamesiD· 1 shared Diaz-Vegas Alexis· 1 shared Federico Tesio TortaiD· 1 shared Harry B. CutleriD· 1 shared Hiroyuki SeimiyaiD· 1 shared Hui JiangiD· 1 shared Jacqueline StöckliiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPhysiology

Tomoyoshi SogaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Renal nutrient loss promotes metabolic health at the expense of increased vulnerability to acute kidney injury

Harry B. Cutler, Diaz-Vegas Alexis, Oliver K Fuller, Kristen C. Cooke, Stewart W. C. Masson, Søren Madsen, Jacqueline Stöckli, Sanae Ashitani, Kaori Igarashi, Tomoyoshi Soga, Liang Gao, Federico Tesio Torta, David Ernest James

This study identifies a renometabolic trade-off where increased urinary nutrient loss protects against obesity but increases vulnerability to acute kidney injury.

bioRxiv · Sep 29, 2026 · PreprintPhysiology

Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer

Takako Ooshio, Yusuke Satoh, Hui Jiang, Tongwei Liu, Kiyonaga Fujii, Takamasa Ishikawa, Kaori Igarashi, Kaori Saitoh, Keiko Kato, Tetsuo Mashima, Shigeki Jin, Kotaro Matoba, Matthias Mack, Tsuyoshi Osawa, Hiroyuki Seimiya, , Masahiro Sonoshita

The paper identifies dual targeting of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer by showing synergistic suppression of PDAC xenograft growth.

bioRxiv · Oct 23, 2024 · PreprintCancer Biology